Ensysce Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held on June 23, 2022. The report was filed on June 27, 2022. Ensysce Biosciences, Inc. is a Delaware corporation with its principal executive offices in La Jolla, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes
No material financial changes were reported in this filing. The primary event was the successful election of directors and the ratification of the independent auditor.
Outlook, Risks, and Unusual Items
The filing contains no management commentary regarding future guidance, risks, contingencies, or unusual items. It strictly details the voting outcomes for the Annual Meeting.
Key Facts for Investors
- Director Election: Stockholders elected three Class I Directors (Andrew B. Benton, William Chang, and Lee Rauch) with terms expiring in 2025. All nominees received a majority of votes cast "FOR" over "AGAINST."
- Auditor Ratification: Stockholders ratified the appointment of the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 24,416,345 votes "FOR" and 181,459 "AGAINST."
- Voting Thresholds: For the director election, abstentions and broker non-votes were not counted as votes cast. For the auditor ratification, abstentions had the effect of a vote "AGAINST."
- Broker Non-Votes: There were 6,768,343 broker non-votes recorded for the director election proposals.